Skip to content

Effects of Aripiprazole on Irritable Bowel Syndrome (IBS)

Comparing effect of Aripiprazole with Nortriptyline on severity of Irritable Bowel Syndrome (IBS)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017012227682N1
Enrollment
84
Registered
2017-03-22
Start date
2017-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Intervention group: Aripiprazole Tab. 5 mg, first one half tab. per day and in the next follow ups if necessary increasing the dose up to 10mg/d till 3 months. Intervention 2: Control
Treatment - Drugs
Intervention group: Aripiprazole Tab. 5 mg, first one half tab. per day and in the next follow ups if necessary increasing the dose up to 10mg/d till 3 months
Control group: Nortriptyline tab. 10mg, first one tab. per day and in the next follow ups if necessary increasing the dose up to 50mg/d till 3 months

Sponsors

Poursina Hakim Clinic
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients with diagnosis of IBS who come to Poursina Hakim clinic in Isfahan city exclusion criteria: patients with concurrent chronic diseases, major depression and severe bipolar disease who need specific psychological treatments; patients who consume psychotropic drugs; noncooperation with executors

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of IBS symptoms. Timepoint: Before trial, then monthly to 3 monnths during trial. Method of measurement: Standard questionnaire.

Secondary

MeasureTime frame
Frequency of bipolar disorder. Timepoint: Before trial, then monthly to 3 monnths during trial. Method of measurement: Standard questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHojjatolah Rahimi

Poursina Hakim Clinic

hakim@mail.mui.ac.ir; hrahimi1390@gmail.com+98 31 3664 0212

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026